^
2d
Enrollment closed
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
2d
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) (clinicaltrials.gov)
P2, N=13, Recruiting, Children's Hospital of Philadelphia | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Jul 2024
Enrollment open • Trial initiation date
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
4d
New P3 trial
|
AFP (Alpha-fetoprotein)
|
Lenvima (lenvatinib)
4d
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
4d
A prospective, open, multi-cohort study of cardonilimab combined with lenvastinib in renal cell carcinoma (ChiCTR2400090483)
P2, N=46, Not yet recruiting, Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
New P2 trial
|
Lenvima (lenvatinib)
4d
An open-label, single-center, prospective study of transarterial chemoembolization (TACE) combined with Adabelimab and lenvatinib mesylate for unresectable advanced hepatocellular carcinoma. (ChiCTR2400090801)
P2, N=30, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University
New P2 trial • Metastases
|
Lenvima (lenvatinib)
4d
New P2 trial
|
Lenvima (lenvatinib)
4d
Efficacy and safety of adebrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a randomized controlled open-label phase II study (ChiCTR2400080080)
P2, N=36, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University | Not yet recruiting --> Recruiting
Enrollment open
|
Lenvima (lenvatinib) • Ariely (adebrelimab)
7d
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov)
P2, N=26, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting
Enrollment closed
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
8d
La prise en charge des cancers médullaires de la thyroïde en 2024. (PubMed, Bull Cancer)
The development of multi-kinase inhibitors cabonzantinib and vandetanib, and RET-targeted inhibitors selpercatinib, has completely changed the therapeutic arsenal for advanced disease, but their prescription is reserved to progressive disease with high tumor volume or to symptomatic disease inaccessible to local treatment in expert centers from the ENDOCAN-TUTHYREF network. Active surveillance is the alternative of choice for slowly progressing disease.
Review • Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
Retevmo (selpercatinib) • Caprelsa (vandetanib)
8d
Lenvatinib-resistant hepatocellular carcinoma promotes malignant potential of tumor-associated macrophages via exosomal miR-301a-3p. (PubMed, Ann Gastroenterol Surg)
Activation of Nrf2 signaling by LR HCC cell-derived exosomal miR-301a-3p skewed the transformation of macrophages to the M2 phenotype. Our study provides new findings on the role of miR-301a-3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
Lenvima (lenvatinib)
9d
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study. (PubMed, Cancer Immunol Immunother)
The combination regimen demonstrated promising efficacy in treating unresectable HCC, accompanied by manageable safety profiles. Furthermore, the results of this investigation suggest that AFP holds promise as predictive biomarkers for this treatment strategy.
Retrospective data • Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
AFP (Alpha-fetoprotein)
|
Tyvyt (sintilimab) • Lenvima (lenvatinib)
9d
New P2 trial
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9d
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov)
P2, N=30, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Aug 2024 --> Dec 2024
Trial primary completion date
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9d
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=39, Completed, Nanfang Hospital, Southern Medical University | Recruiting --> Completed
Trial completion
|
Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • oxaliplatin
10d
PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov)
P2, N=58, Active, not recruiting, The Netherlands Cancer Institute | Trial completion date: Mar 2025 --> Mar 2026
Trial completion date
|
TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
10d
Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC). (PubMed, BMC Pulm Med)
This study encapsulates the research endeavors and treatment advancements of RET rearrangement solid tumors within the Chinese healthcare landscape, specifically highlighting the diverse real-world therapeutic approaches and their effectiveness in managing advanced RET rearrangement NSCLC among Chinese patients. Notably, targeted RET inhibitors like Pralsetinib have emerged as potent therapeutic agents, exhibiting remarkable efficacy and a manageable safety profile in this patient cohort. These findings underscore the potential of Pralsetinib and similar targeted therapies as novel treatment options for individuals with RET fusion-positive NSCLC.
Journal • HEOR • Real-world evidence • Real-world
|
RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B)
|
RET fusion • RET rearrangement • RET positive
|
Gavreto (pralsetinib)
10d
BAIAP2L2 promotes the malignancy of hepatocellular carcinoma via GABPB1-mediated reactive oxygen species imbalance. (PubMed, Cancer Gene Ther)
BAIAP2L2 inhibits the levels of reactive oxygen species (ROS) by regulating GABPB1, thereby promoting cancer properties in HCC and reducing the sensitivity of HCC to lenvatinib. In summary, this study elucidates the role and underlying mechanism of BAIAP2L2 in HCC, providing a potential biomarker and therapeutic target for this disease.
Journal
|
BAIAP2 (BAR/IMD Domain Containing Adaptor Protein 2)
|
Lenvima (lenvatinib)
10d
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer. (PubMed, Clin Cancer Res)
The YAP-HER3 axis is crucial for the survival and adaptive resistance of high YAP-expressing RET-aberrant cancer cells treated with RET-TKIs. Combining YAP/HER3 inhibition with RET-TKIs represents a highly potent strategy for initial treatment.
Journal
|
RET (Ret Proto-Oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
RET fusion • ERBB3 expression • RET expression • RET positive
|
Gilotrif (afatinib) • Retevmo (selpercatinib) • Gavreto (pralsetinib) • Visudyne (verteporfin)
10d
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (clinicaltrials.gov)
P2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Surgery
|
RET (Ret Proto-Oncogene)
|
Retevmo (selpercatinib)
11d
N6-Methyladenosine (m6A) modification activates serine synthesis pathway to mediate therapeutic resistance in liver cancer. (PubMed, Mol Ther)
STM2457 treatment attenuated the serine synthesis pathway, induced oxidative stress, and sensitized HCC cells to sorafenib and lenvatinib treatments. In conclusion, our findings suggest that targeting m6A could be a potential therapeutic strategy for HCC treatment.
Journal
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PHGDH (Phosphoglycerate Dehydrogenase) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • METTL3 (Methyltransferase Like 3)
|
MYC overexpression • MYC expression
|
sorafenib • Lenvima (lenvatinib)
13d
Trial completion date
|
Keytruda (pembrolizumab) • sunitinib • everolimus • Lenvima (lenvatinib)
14d
New P2 trial
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
15d
Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. (PubMed, Front Pharmacol)
Compared to RT + S, RT + L had good efficacy in the treatment of hepatocellular carcinoma with PVTT. Validation is needed in prospective studies with larger sample sizes.
Retrospective data • Journal
|
AFP (Alpha-fetoprotein)
|
sorafenib • Lenvima (lenvatinib)
15d
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report. (PubMed, Case Rep Oncol)
To date, this patient continues to show a near complete response to this treatment regimen. To our knowledge, this is the first documented case of SMARCB1-deficient RMC without hemoglobinopathy to receive this treatment regimen and show such a response.
Journal • Metastases
|
SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
15d
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. (PubMed, World J Gastroenterol)
BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.
Retrospective data • Journal • Metastases
|
AFP (Alpha-fetoprotein)
|
Lenvima (lenvatinib) • AiRuiKa (camrelizumab)
15d
Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy. (PubMed, World J Gastrointest Oncol)
If, following downstaging, the patient qualifies for liver resection based on locally prevalent resectability criteria, then such therapy is labelled as conversion (from unresectable to resectable) therapy. In unresectable patients treated by a combination of treatment options, serological markers like neutrophil-to-lymphocyte ratio and alpha-fetoprotein are reported to predict treatment responses, thus enabling personalized medicine.
Clinical data • Journal
|
AFP (Alpha-fetoprotein)
|
Lenvima (lenvatinib)
15d
Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report. (PubMed, World J Gastrointest Oncol)
PDOs for drug sensitivity contribute to screening effective chemotherapy drugs for advanced pCCA, promoting conversion therapy and improving the prognosis.
Journal • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein)
|
cisplatin • gemcitabine • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
16d
Long-term safety of selpercatinib for Rearrenged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. (PubMed, Oncologist)
Long-term treatment with selpercatinib is feasible. AEs are manageable with dose modifications, allowing most patients to continue safely on therapy.
Journal • Adverse events • Metastases
|
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation • RET positive
|
Retevmo (selpercatinib)
16d
Study on the Synergistic Mechanism of Photodynamic Therapy Combined With Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma. (PubMed, Lasers Surg Med)
Our findings suggest that Erastin or Lenvatinib can enhance the induction of ferroptosis in cholangiocarcinoma cells by photodynamic therapy by increasing intracellular ROS and inhibiting intracellular antioxidant pathways.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2)
|
GPX4 expression • SLC7A11 expression
|
Lenvima (lenvatinib) • erastin
17d
Trial completion • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
18d
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Tianjin Medical University Cancer Institute and Hospital | N=120 --> 80 | Trial primary completion date: Jan 2024 --> May 2024
Enrollment change • Trial primary completion date • IO biomarker • Metastases
|
Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
19d
Ginsenoside Rh1 regulates the immune microenvironment of hepatocellular carcinoma via the glucocorticoid receptor. (PubMed, J Integr Med)
G-Rh1 can regulate the immune microenvironment of HCC by targeting GR, thus increasing the antitumor effect of lenvatinib. Please cite this article as: Wang XH, Fu YL, Xu YN, Zhang PC, Zheng TX, Ling CQ, Feng YL. Ginsenoside Rh1 regulates the immune microenvironment of hepatocellular carcinoma via the glucocorticoid receptor. J Integr Med. 2024; Epub ahead of print.
Journal
|
CD8 (cluster of differentiation 8) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
|
Lenvima (lenvatinib)
19d
Gene-expression profile analysis to disclose diagnostics and therapeutics biomarkers for thyroid carcinoma. (PubMed, Comput Biol Chem)
Then we detected 6 repurposable drug molecules (Entrectinib, Imatinib, Ponatinib, Sorafenib, Retevmo, and Pazopanib) by molecular docking with KGs-mediated receptor proteins, ADME/T analysis, and cross-validation with the independent receptors. Therefore, these findings might be useful resources for wet lab researchers and clinicians to consider an effective treatment strategy against THCA.
Journal • Gene Expression Profile
|
TOP2A (DNA topoisomerase 2-alpha) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • RUNX2 (RUNX Family Transcription Factor 2)
|
KIM1 expression • TIMP1 expression
|
sorafenib • Rozlytrek (entrectinib) • imatinib • Iclusig (ponatinib) • pazopanib • Retevmo (selpercatinib)
20d
Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC. (PubMed, Adv Sci (Weinh))
Treatment with liposomes carrying siRNAs targeting IGF2BP3 or the glycolysis inhibitor 2-DG restored lenvatinib sensitivity in vivo. These findings highlight the connection between metabolic reprogramming and epigenetic regulation and suggest that targeting metabolic pathways may offer new strategies to overcome lenvatinib resistance in HCC.
Journal
|
IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGFBP3 elevation
|
Lenvima (lenvatinib)
23d
Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. (PubMed, Front Oncol)
In the absence of any prospective comparative study and to evaluate in a real-world context the clinical benefit of re-administering a PD-1 inhibitor (pembrolizumab 200 mg i.v. every 3 weeks, Q3W) with a multi-kinase inhibitor (lenvatinib, but at a reduced dose 10 mg p.o. daily due to its known toxicity) in this frail population of unmet need, we conducted here a retrospective comparison of LEAP-004-proposed combination with CC (carboplatin 4 AUC and dacarbazine 850 mg/m2 i.v. Q3W) in melanoma patients who relapsed to both checkpoint inhibitors, either in combinatorial or in sequential setting, between July 2022 and January 2024. Grade 3-5 treatment-related adverse events were documented in 48.7% (pembrolizumab/lenvatinib) and 75.6% (CC) of patients (p=0.034), which led to treatment discontinuation in 10.3% and 17.8% of cases, respectively. This is the first comparative study in patients with metastatic melanoma refractory to PD-1/CTLA-4 inhibition and showed significantly longer outcomes in cases treated with pembrolizumab/lenvatinib versus CC.
Journal • Metastases
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • dacarbazine
23d
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. (PubMed, Liver Cancer)
In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79-1.06). Responses were seen even in those patients with more severe disease at baseline. Tumor responses occurred early and were durable.
P3 data • Journal
|
AFP (Alpha-fetoprotein)
|
sorafenib • Lenvima (lenvatinib)
23d
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. (PubMed, Liver Cancer)
Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC)...The presence of MPR or pCR could improve prognosis in patients with initially uHCC who underwent conversion surgery following triple therapy. The PR may become a surrogate marker for predicting the prognosis of these patients.
Journal • PD(L)-1 Biomarker • IO biomarker • Surgery
|
AFP (Alpha-fetoprotein)
|
Lenvima (lenvatinib)
25d
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC (clinicaltrials.gov)
P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
RET (Ret Proto-Oncogene)
|
RET fusion
|
Retevmo (selpercatinib)
28d
Management of follicular thyroid carcinoma. (PubMed, Eur Thyroid J)
Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs. In addition, given that renin-angiotensin system (RAS) is the most common driver gene for FTC, it is also important to develop RAS inhibitors.
Review • Journal
|
TERT (Telomerase Reverse Transcriptase)
|
TERT mutation • TERT promoter mutation
|
sorafenib • Lenvima (lenvatinib)
28d
New trial • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
28d
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)